Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Trends in Pharmacological Sciences|March 19, 2021
Efflux Limits Tumor Drug Delivery Despite Disrupted BBBJessica I Griffith, Jann N Sarkaria, William F ElmquistPharmaceutics|December 16, 2020
Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain TumorsJessica I Griffith, Sneha Rathi, Wenqiu Zhang, et al.Journal of Internal Medicine|January 18, 2022
The influence of the blood-brain barrier in the treatment of brain tumoursSneha Rathi, Jessica I Griffith, Wenjuan Zhang, et al.The Journal of Pharmacology and Experimental Therapeutics|October 19, 2021
Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic ActivityJessica I Griffith, Minjee Kim, Daniel J Bruce, et al.Pharmaceutical Research|January 26, 2018
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast CancerAfroz S Mohammad, Jessica I Griffith, Chris E Adkins, et al.Biorxiv : the Preprint Server for Biology|February 27, 2026
In Vivo Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft modelCaroline D Doherty, Sonia Jain, Lauren L Ott, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma ModelsSonia Jain, Jessica I Griffith, Kendra A Porath, et al.Neuro-Oncology Advances|September 8, 2022
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenograftsKendra A Porath, Michael S Regan, Jessica I Griffith, et al.Pageof 1